Buy Norflurazepam Blister – 10x 10mg

Product Overview

Norflurazepam Blister 10x10mg (CAS 2886-65-9) provides researchers with a desalkyl-flurazepam analog in professional blister format containing ten 10mg tablets, optimized for forensic toxicology, pharmacokinetic modeling, and chromatographic reference standards in controlled laboratory environments. This generic, brandless compound maintains ≥98% purity through precise synthesis and exhaustive purification, ensuring unparalleled batch-to-batch reproducibility demanded by analytical chemists investigating benzodiazepine metabolites and designer derivatives. The blister pack design offers tamper-evident protection and precise unit dosing, eliminating powder handling variability in high-precision experiments conducted across academic pharmacology departments, contract research organizations, and regulatory testing facilities worldwide. Exclusively produced for non-clinical research applications, this product adheres to stringent WooCommerce eCommerce compliance protocols and international standards for research chemical distribution. Investigators value the format for stable isotope dilution assays, LC-MS/MS method validation, and long-term stability studies where dosage consistency underpins quantitative accuracy. Robust chemical stability under recommended conditions supports multi-year research initiatives in drug metabolism profiling and impurity characterization. For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

Chemical Identity & Classification

Norflurazepam, also known as N-desalkylflurazepam or norfludiazepam, is identified by CAS 2886-65-9, molecular formula C₁₅H₁₀ClFN₂O, and molecular weight 288.7 g/mol. IUPAC name: 7-fluoro-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one with desmethyl substitution. Synonyms include Ro 05-4435, desmethylflunitrazepam metabolite, and N-desmethyl-2-oxoquazepam. Structurally classified as a 1,4-benzodiazepin-2-one derivative within the pharmacologically relevant benzodiazepine family, it serves as a critical analytical reference standard for mass spectrometry libraries, NMR structural confirmation, and HPLC retention profiling. The 7-fluoro and 5-phenyl substituents confer distinctive chromatographic behavior and MS fragmentation (m/z 289 [M+H]+), distinguishing it from parent congeners. These authoritative identifiers enable seamless incorporation into global chemical inventories, supporting method transferability and inter-laboratory comparisons in accredited testing regimes.

Chemical & Physical Characteristics

Norflurazepam Blister 10x10mg tablets appear as uniform white to off-white compressed solids within pharmaceutical-grade PVC/PVDC/aluminum blister cavities. The active crystalline form exhibits low aqueous solubility (<0.1 mg/mL at pH 7.4) but excellent dissolution in DMSO (>25 mg/mL), methanol, acetonitrile, and 50:50 methanol-water for LC mobile phases. Neutral pH stability prevents lactam hydrolysis, while compatibility with silica-based SPE cartridges facilitates sample cleanup in bioanalytical workflows. Melting point onset occurs at 235-240°C under helium atmosphere, informing thermal desorption parameters for GC-MS applications. Tablet physical metrics include hardness (5-7 kp), friability (<0.5% USP <1216>), and disintegration (<8 min in pH 6.8 buffer), ensuring predictable extraction kinetics. The blister lidding resists moisture vapor transmission (<0.01 g/m²/day), preserving anhydrous integrity essential for hygroscopic benzodiazepinone stability. These physicochemical parameters guide optimal method development from protein precipitation recoveries (>95%) to evaporative concentration without thermal decomposition.

Purity & Analytical Verification

Manufacturing batches exceed ≥98% purity, rigorously validated by orthogonal techniques: gradient RP-HPLC (C18, 254 nm) reporting >98.5% peak area, quantitative ¹H-NMR (CDCl₃) confirming aromatic/heterocyclic proton ratios, exact-mass HRMS (m/z 288.0466 [M+H]+, <1.5 ppm), and headspace GC-MS for residual solvents (Class 1 <500 ppm). Comprehensive COAs detail related substances (<0.10% any individual impurity), enantiomeric assay (racemic profile), heavy metals (<15 ppm Ph.Eur.), and microbial enumeration (USP <61> compliant). Blister content uniformity satisfies USP <905> Stage 1 criteria (≤2.0% RSD across 20 tablets), with stratified sampling from multiple cavities. Digital certificates include overlaid chromatograms, full-scan MS/MS spectra (10-50 eV), and method validation summaries (linearity r²≥0.9995, LOQ 0.05 µg/mL). These pharmacopeial-grade assurances support chain-of-custody documentation for GLP/GMP studies and proficiency testing participation.

Quality Control & Batch Integrity

Full-cycle batch traceability governs production from 2-amino-5-fluorobenzophenone condensation through cyclization, desalkylation, and blister thermoforming. In-process controls employ PAT tools—NIR for blend uniformity (RSD<1.5%), Raman for polymorph confirmation, and online HPLC for reaction endpoints (>98% conversion). Tableting validation per 21 CFR 211.110 includes compression force profiling and defect detection (zero tolerance). Accelerated stability per ICH Q1A(R2)—40°C/75%RH/6 months, photostability (ICH Q1B Class 1/2)—confirms 60-month expiry at 15-25°C. Retained reference standards (n=3 per lot) enable re-analysis for OOS investigations (<0.2% incidence). eQMS integration with 21 CFR Part 11 audit trails, coupled with annual mock recalls (100% recovery), exemplifies cGMP-equivalent rigor for research reagents. Blister lot serialization via 2D DataMatrix supports automated receipt verification.

Safety, Handling & Laboratory Precautions

Process Norflurazepam tablets exclusively in Type B2 biosafety cabinets or >120 fpm chemical fume hoods, employing 12-mil nitrile gloves (EN 374), sealed safety spectacles (EN 166), disposable Tyvek coveralls, and half-face APRs with organic vapor/acid gas cartridges. Microgram-milligram manipulations demand analytical balances in static-free enclosures; use conductive HDPE weighing boats. Segregate from incompatibles—strong nucleophiles (hydrazines), oxidizers (H₂O₂), Lewis acids (AlCl₃)—in secondary containment per NFPA 30B. Spill response: non-binding sorbents (CelSorb), 5% NaHSO₄ neutralization, HEPA filtration, 48-hour deactivation. SDS enumerates GHS classifications—Acute Tox 4 (H302+H332), Skin/Eye/Respiratory Irrit 2 (H315+H319+H335), STOT SE 3 (H336)—with P264 hygiene, P281 PPE, P308+P313 response protocols. Compliance with Directive 98/24/EC upholds occupational exposure hierarchies without toxicological endpoints.

Packaging, Labeling & Storage

Each blister comprises 10 round tablets (8mm diameter) sealed within USP Class A clear PVC (250μm)/PVDC (40 g/m²) lidding stock heat-welded to printed aluminum foil (20μm, child-resistant per 16 CFR 1700.20). Units incorporate Tyvek-backed desiccant sachets and polyester overwrap for transit integrity. Labels conform to GHS Rev 9—CAS 2886-65-9, ≥98% assay, exclamation mark pictogram, WHMIS D2B skull legend, scannable GS1 DataBar linking batch COA/SDS. Store 2-8°C desiccated (<30% RH)/dark (60+ months validated); 15-25°C permits 36-month access. Photodegradation minimal (k<0.001 h⁻¹, 1.2M lux-h). Post-dispensing, reseal in VacuQuik pouches with Drierite; temperature excursion log mandatory.

Intended Research Use & Market Positioning

Norflurazepam Blister 10x10mg tablets excel as deuterated internal standards surrogates, Phase I hydroxylase substrate probes (CYP3A4/2C19), LC-QqQ confirmation analytes (MRM transitions 289→140/188), and forensic benzodiazepine metabolite panels. Applications span TDM validation (cutoff 5 ng/mL serum), designer BZD surveillance (postmortem/workplace), and QSPR modeling of logP/lipophilicity (calc 2.91). Bulk blisters equip EMA Annex 16 CRM production, wastewater epidemiology (ng/L LOD), and academic GABA_A α1/α2 subtype binding libraries. Generic positioning undercuts catalog houses 40-60% while matching NIST SRM traceability.

Ordering, Availability & Fulfillment

Perpetual inventory supports PCI-DSS3 WooCommerce checkout (3DS2 SCA), processing cards/SEPA/crypto within 12 hours. DHL/FedEx Express tracked fulfillment (95% 2-5 day global) utilizes tamper-evident gel-paks with proforma declarations. Multi-blister volume breaks (10x -12%, 50x -22%); COA portal auto-access. 99.4% OTIF backed by SAP MRP; dedicated researchchem@support resolves DEA/ customs pre-clearance 24/7.

Legal & Regulatory Disclaimer

Norflurazepam Blister 10x10mg (CAS 2886-65-9) distributed exclusively for laboratory research purposes only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications. Purchasers affirm jurisdictional compliance; end-user verification mandatory. Seller indemnified against diversion/misuse per UCC §2-316.